Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 15/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020778 | 0.96 | PGR (0.58) | PGRADRA2ANPY5RMCHR1AR | |
| SCHEMBL3024039 | 0.87 | PGR (0.65) | PGRAR | |
| SCHEMBL3007266 | 0.87 | PGR (0.60) | PGRADRA2ANPY5RMCHR1AR | |
| SCHEMBL3027911 | 0.86 | PGR (0.64) | PGRAR | |
| SCHEMBL3021456 | 0.85 | PGR (0.46) | PGRAR | |
| SCHEMBL3026280 | 0.84 | PGR (0.62) | PGRAR | |
| SCHEMBL3021308 | 0.84 | PGR (0.67) | PGRAR | |
| SCHEMBL3022953 | 0.83 | PGR (0.55) | PGRAR | |
| SCHEMBL3019165 | 0.82 | PGR (0.65) | PGRAR | |
| SCHEMBL3020619 | 0.82 | PGR (0.64) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | claimed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | claimed |
| EP-2137145-A2 | CYANOPYRROL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008109055-A2 | CYANOPYRROLE SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | claimed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | claimed |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2137145-A2 | CYANOPYRROL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008109055-A2 | CYANOPYRROLE SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | FSHR, GNRHR, CYP19A1 | PGR 7/4885ADRA2A 864/4885NPY5R 169/4885 |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | PKD1, PKD2, SHBG | PGR 20/4885ADRA2A 2396/4885NPY5R 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.